Fate Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Fate Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Fate Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Fate Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumours. Its major products include multiplexed-engineered T-cell and natural killer (NK) cell product candidates. Its products are designed for use in treating various autoimmune diseases and are intended to be administered alone or in combination with standard-of-care therapies. The company also has research collaborations with companies, academic centers, and medical centers for the advancement of products and technologies. The company targets markets that require scalable and accessible cell therapies. Fate Therapeutics is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
12278 Scripps Summit Drive, San Diego, California, 92131
Website
fatetherapeutics.com
Telephone
1 858 8751803
No of Employees
161
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FATE (NASD)
Revenue (2024)
$13.6M
-78.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-15.7%
(2024 vs 2023)
Market Cap*
$277.9M
Net Profit Margin (2024)
XYZ
-439.5%
(2024 vs 2023)
* As of and is in US$
Fate Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline:- |
| Off-the-shelf, iPSC-derived Cellular Immunotherapies: |
| FT819 for B-cell Malignancies and Chronic Lymphocytic Leukemia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In April, the company received approval from the US Food and Drug Administration for Regenerative Medicine Advanced Therapy designation to FT819, an investigational, off-the-shelf, iPSC-derived CAR T-cell therapy in Phase 1 clinical development for the treatment of active moderate to severe systemic lupus erythematosus, including lupus nephritis. |
| 2022 | Contracts/Agreements | In June, the company expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd to include the development of chimeric antigen receptor (CAR) NK cell collaboration candidates. |
| 2022 | Regulatory Approval | In January, the company secured approval from FDA for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate. |
Competitor Comparison
| Key Parameters | Fate Therapeutics Inc | Johnson & Johnson | AstraZeneca Plc | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Switzerland | United States of America |
| City | San Diego | New Brunswick | Cambridge | Basel | Princeton |
| State/Province | California | New Jersey | Cambridgeshire | Basel-Stadt | New Jersey |
| No. of Employees | 161 | 138,200 | 96,100 | 75,267 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Rastetter, Ph.D. | Chairman | Executive Board | 2011 | 76 |
| Bahram Valamehr, Ph.D. | Chief Executive Officer; President | Senior Management | 2025 | 49 |
| Kamal Adawi | Chief Financial Officer | Senior Management | 2025 | - |
| Cindy R. Tahl | Chief Legal & Compliance Officer | Senior Management | - | 52 |
| John D. Mendlein, Ph.D. | Vice Chairman | Executive Board | 2011 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer